In an adult on mirtazapine 30 mg daily with persistent generalized anxiety disorder symptoms, should I add buspirone or switch to escitalopram (Lexapro)?

Switch to Escitalopram (Lexapro)

For a patient on mirtazapine 30 mg with persistent GAD symptoms, I recommend switching to escitalopram rather than adding buspirone. Escitalopram is FDA-approved for GAD and has robust evidence for efficacy, while buspirone augmentation has shown inferior tolerability and no clear advantage in this clinical scenario.

Rationale for Switching to Escitalopram

FDA-Approved First-Line Agent

Escitalopram is FDA-approved specifically for GAD treatment 1, demonstrating efficacy in multiple 8-week trials with continued benefit in long-term studies 1. In GAD trials, escitalopram showed significant improvement on Hamilton Anxiety Scale scores compared to placebo, with 10-20 mg/day dosing 2, 3.

Mirtazapine's Limited Role in GAD

While mirtazapine shows some efficacy for anxiety symptoms in depression 4, 5, it is not FDA-approved for GAD and evidence is primarily from open-label studies 6. The most recent systematic review 4 found mirtazapine comparable to SSRIs for anxiety in major depressive disorder, but your patient has primary GAD—a different indication requiring different treatment priorities.

Why Not Buspirone Augmentation?

The STAR*D trial data is instructive here: when augmenting antidepressants, buspirone had significantly higher discontinuation rates due to adverse events (20.6%) compared to bupropion (12.5%, p<0.001) 7. While buspirone showed similar efficacy to other augmentation strategies, its tolerability profile is concerning 8.

More importantly, the evidence for buspirone augmentation comes from depression trials, not GAD-specific studies. The FDA label for buspirone 9 notes that pediatric GAD trials showed no significant differences between buspirone and placebo for GAD symptoms at recommended adult doses, raising questions about its efficacy even as monotherapy.

Practical Switching Strategy

Cross-Titration Approach

1. Start escitalopram 10 mg daily while continuing mirtazapine 30 mg
2. After 1 week, begin tapering mirtazapine by 7.5 mg every 3-5 days
3. Increase escitalopram to 20 mg daily after 2-4 weeks if needed for optimal response
4. Target dose: escitalopram 10-20 mg daily 1

Expected Timeline

• Initial anxiety improvement: 2-4 weeks
• Full response: 6-8 weeks 2
• Long-term maintenance prevents relapse (relapse risk 4× higher with placebo) 2

Important Caveats

Sleep Considerations

Mirtazapine has strong sedating properties that may have been beneficial for sleep 10. When switching, monitor for insomnia emergence. If sleep disturbance occurs, consider:

• Temporary low-dose mirtazapine (7.5-15 mg) at bedtime during transition
• Sleep hygiene optimization
• Short-term trazodone if needed

Anxiety with Depression

If your patient has comorbid depressive symptoms alongside GAD, this strengthens the case for escitalopram, which is FDA-approved for both conditions 1. The recent evidence 4 suggests mirtazapine may be preferred when anxiety occurs in the context of major depressive disorder, but that's not your clinical scenario.

Weight and Appetite

Mirtazapine significantly improves appetite and weight 10. If your patient benefited from these effects, counsel about potential weight neutrality with escitalopram. Conversely, if weight gain was problematic on mirtazapine, escitalopram offers an advantage.

Why This Beats Augmentation

Switch strategies and augmentation strategies show similar efficacy in second-step treatment trials 7. However, switching to an FDA-approved, first-line GAD agent (escitalopram) is more rational than augmenting an off-label agent (mirtazapine) with a poorly-tolerated medication (buspirone) that failed to show efficacy in pediatric GAD trials 9.

The 2023 ACP guidelines 7 found no differences between various switch strategies (including switching to escitalopram), supporting the safety and efficacy of this approach. Importantly, comorbid anxiety did not affect the comparative efficacy of switch strategies 7, meaning escitalopram should work regardless of anxiety severity.

Monitoring

• Week 2: Assess tolerability, sleep, early anxiety response
• Week 4-6: Evaluate GAD-7 or HAM-A scores; consider dose increase to 20 mg if partial response
• Week 8-12: Assess full response; if inadequate, consider adding CBT rather than another medication 7
• Adverse events: Monitor for activation, GI symptoms (typically mild-moderate and transient) 2, 3

The evidence strongly favors switching to escitalopram as a more logical, evidence-based approach than buspirone augmentation for persistent GAD symptoms.